PTAB Condemns Bristol-Myers' 'Whac-A-Mole Strategy'
The Patent Trial and Appeal Board has ended Amgen Inc.'s challenge to a now-disclaimed patent covering Bristol-Myers Squibb Co.'s blockbuster cancer drug Opdivo, and denied Bristol-Myers' request to pursue a replacement...To view the full article, register now.
Already a subscriber? Click here to view full article